New Risk • Jul 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Share price has been highly volatile over the past 3 months (15% average weekly change). Market cap is less than US$10m (€4.94m market cap, or US$5.62m). Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Independent Director Damien Graton was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • May 17
SAS Florentaise, Annual General Meeting, Jun 20, 2025 SAS Florentaise, Annual General Meeting, Jun 20, 2025. Location: grand patis, saint mars du desert France Reported Earnings • Mar 31
First half 2024 earnings released First half 2024 results: €0.28 loss per share. Net loss: €2.27m (flat on 1H 2023). Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to €2.32, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 13x in the Chemicals industry in Germany. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €1.89, the stock trades at a trailing P/E ratio of 29.3x. Average trailing P/E is 12x in the Chemicals industry in Germany. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). Revenue has declined by 16% over the past year. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.1% net profit margin). Market cap is less than US$100m (€24.6m market cap, or US$26.3m). Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to €3.86, the stock trades at a trailing P/E ratio of 56.9x. Average trailing P/E is 11x in the Chemicals industry in Germany. Reported Earnings • Nov 02
Full year 2023 earnings released: EPS: €0.07 (vs €0.49 in FY 2022) Full year 2023 results: EPS: €0.07 (down from €0.49 in FY 2022). Revenue: €54.5m (down 14% from FY 2022). Net income: €562.0k (down 80% from FY 2022). Profit margin: 1.0% (down from 4.5% in FY 2022). New Risk • Sep 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.9% operating cash flow to total debt). High level of non-cash earnings (21% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2022 fiscal period end). Market cap is less than US$100m (€54.0m market cap, or US$57.6m). New Risk • Sep 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.9% operating cash flow to total debt). High level of non-cash earnings (21% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2022 fiscal period end). Market cap is less than US$100m (€61.2m market cap, or US$65.6m). Board Change • May 11
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Damien Graton was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.